Top Markets
Coin of the day
Sunny Pharmtech Inc. Sunny Pharmtech Inc.

Sunny Pharmtech Inc.

6676
Clasificación en acciones #24082
Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses... Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing and global sales. Its operations encompass both active pharmaceutical ingredients (APIs) and finished medicinal products. The company's extensive product range includes: A lidocaine ointment, which functions as an anesthetic lubricant for intubation procedures and offers temporary relief from discomfort associated with minor burns, sunburn, skin abrasions, and insect stings. Cyanocobalamin injections, prescribed to treat vitamin B12 deficiency and pernicious anemia caused by malabsorption issues. Nitrofurantoin capsules, used in the treatment of urinary tract infections. Aminocaproic acid tablets, indicated for managing certain blood disorders and conditions involving excessive proteolytic enzyme activity. Carboprost tromethamine injections, utilized in therapeutic abortions and to address postpartum hemorrhage.
Precio por acción
$0.38476824
Última sincronización: 2026-08-21
Capitalización bursátil
$65.29M
Cambio (1 día)
-3.20%
Cambio (1 año)
-40.81%
País
TW
Comercio Sunny Pharmtech Inc. (6676)

Categoría

Ganancias de Sunny Pharmtech Inc. (6676)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Sunny Pharmtech Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Sunny Pharmtech Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH